MicroRNAs in osteosarcoma: From biological players to clinical contributors, a review

Journal of International Medical Research

Volumn 41, Issue 1, 2013, Pages 1-12

  Zhou, Guangxin ^a   Shi, Xin ^a   Zhang, Junfeng ^b   Wu, Sujia ^a   Zhao, Jianning ^a  

^a JINLING HOSPITAL   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Diagnosis; microRNA; Osteosarcoma; Prognosis; Treatment; Tumourigenesis

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; MICRORNA; MICRORNA 125B; MICRORNA 140; MICRORNA 143; MICRORNA 199A; MICRORNA 20A; MICRORNA 21; MICRORNA 34; MICRORNA 93; UNCLASSIFIED DRUG;

BIOLOGICAL ACTIVITY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; DIAGNOSTIC VALUE; DRUG DESIGN; DRUG EFFICACY; GENE FUNCTION; GENE OVEREXPRESSION; GENE REGULATORY NETWORK; GENE TARGETING; HUMAN; LUNG METASTASIS; METASTASIS INHIBITION; NON INVASIVE MEASUREMENT; NONHUMAN; OSTEOSARCOMA; REVIEW; RNA ANALYSIS; RNA SYNTHESIS; TREATMENT RESPONSE; TUMOR INVASION;

EID: 84878404863     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513475959     Document Type: Review

References (52)

1. Marina N, Gebhardt M, Teot L, et al. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9: 422-441.
2. Bielack SS, Marina N, Ferrari S, et al. Osteosarcoma: the same old drugs or more? J Clin Oncol 2008; 26: 3102-3103. (author reply 3104-3105.
3. Longhi A, Errani C, De Paolis M, et al. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006; 32: 423-436.
4. Broadhead ML, Clark JC, Myers DE, et al. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011; 2011: 959248.
5. Kansara M and Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol 2007; 26: 1-18.
6. Esquela-Kerscher A and Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
7. Calin GA and Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
8. Carrington JC and Ambros V. Role of microRNAs in plant and animal development. Science 2003; 301: 336-338.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
10. He L and Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531.
11. Lowery AJ, Miller N, McNeill RE, et al. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 2008; 14: 360-365.
12. Wu X, Piper-Hunter MG, Crawford M, et al. MicroRNAs in the pathogenesis of lung cancer. J Thorac Oncol 2009; 4: 1028-1034.
13. Rachagani S, Kumar S and Batra SK. MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett 2010; 292: 8-16.
14. Slaby O, Svoboda M, Michalek J, et al. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009; 8: 102.
15. Lee RC, Feinbaum RL and Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854.
16. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-739.
17. Farh KK, Grimson A, Jan C, et al. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science 2005; 310: 1817-1821.
18. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529.
19. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
20. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-658.
21. Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-2136.
22. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-13949.
23. Kong YW, Ferland-McCollough D, Jackson TJ, et al. MicroRNAs in cancer management. Lancet Oncol 2012; 13: e249-e258.
24. Liu X, Liu L, Xu Q, et al. MicroRNA as a novel drug target for cancer therapy. Expert Opin Biol Ther 2012; 12: 573-580.
25. Lulla RR, Costa FF, Bischof JM, et al. Identification of differentially expressed microRNAs in osteosarcoma. Sarcoma 2011; 2011: 732690.
26. Duan Z, Choy E, Harmon D, et al. MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther 2011; 10: 1337-1345.
27. Maire G, Martin JW, Yoshimoto M, et al. Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet 2011; 204: 138-146.
28. Thayanithy V, Sarver AL, Kartha RV, et al. Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone 2012; 50: 171-181.
29. Ziyan W, Shuhua Y, Xiufang W, et al. MicroRNA-21 is involved in osteosarcoma cell invasion and migration. Med Oncol 2011; 28: 1469-1474.
30. Liu LH, Li H, Li JP, et al. miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. Biochem Biophys Res Commun 2011; 416: 31-38.
31. Zhang H, Cai X, Wang Y, et al. microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep 2010; 24: 1363-1369.
32. Chen X, Guo X, Zhang H, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009; 28: 1385-1392.
33. Noguchi S, Mori T, Hoshino Y, et al. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett 2011; 307: 211-220.
34. Osaki M, Takeshita F, Sugimoto Y, et al. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther 2011; 19: 1123-1130.
35. French LE and Tschopp J. Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immuneprotection and cell turnover. Behring Inst Mitt 1996; 156-160.
36. Gordon N and Kleinerman ES. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat Res 2009; 152: 497-508.
37. Huang G, Nishimoto K, Zhou Z, et al. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 2012; 72: 908-916.
38. Montanini L, Lasagna L, Barili V, et al. MicroRNA cloning and sequencing in osteosarcoma cell lines: differential role of miR-93. Cell Oncol (Dordr) 2012; 35: 29-41.
39. Song B, Wang Y, Xi Y, et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009; 28: 4065-4074.
40. He C, Xiong J, Xu X, et al. Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun 2009; 388: 35-40.
41. Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17: 1298-1307.
42. Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745-752.
43. Corney DC, Flesken-Nikitin A, Godwin AK, et al. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesionindependent growth. Cancer Res 2007; 67: 8433-8438.
44. Gougelet A, Pissaloux D, Besse A, et al. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer 2011; 129: 680-690.
45. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
46. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable bloodbased markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
47. Park NJ, Zhou H, Elashoff D, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009; 15: 5473-5477.
48. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010; 28: 655-661.
49. Chen X, Gao C, Li H, et al. Identification and characterization of microRNAs in raw milk during different periods of lactation, commercial fluid, and powdered milk products. Cell Res 2010; 20: 1128-1137.
50. Garzon R, Marcucci G and Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
51. Bader AG, Brown D, Stoudemire J, et al. Developing therapeutic microRNAs for cancer. Gene Ther 2011; 18: 1121-1126.
52. Liu C and Tang DG. MicroRNA regulation of cancer stem cells. Cancer Res 2011; 71: 5950-5954.